These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22935585)

  • 21. How I treat hypereosinophilic syndromes.
    Klion AD
    Blood; 2009 Oct; 114(18):3736-41. PubMed ID: 19692700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
    Tefferi A; Gotlib J; Pardanani A
    Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.
    Riccio AM; Dal Negro RW; Micheletto C; De Ferrari L; Folli C; Chiappori A; Canonica GW
    Int J Immunopathol Pharmacol; 2012; 25(2):475-84. PubMed ID: 22697079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mepolizumab and eosinophil-mediated disease.
    Walsh GM
    Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What targeting eosinophils has taught us about their role in diseases.
    Bochner BS; Gleich GJ
    J Allergy Clin Immunol; 2010 Jul; 126(1):16-25; quiz 26-7. PubMed ID: 20434203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. L6. Eosinophilic granulomatosis with polyangiitis: future therapies.
    Moosig F
    Presse Med; 2013 Apr; 42(4 Pt 2):510-2. PubMed ID: 23453508
    [No Abstract]   [Full Text] [Related]  

  • 27. The spectrum of therapeutic activity of mepolizumab.
    Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
    Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
    [No Abstract]   [Full Text] [Related]  

  • 28. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
    Chen MM; Roufosse F; Wang SA; Verstovsek S; Durrani SR; Rothenberg ME; Pongdee T; Butterfield J; Lax T; Wechsler ME; Stein ML; Ogbogu PU; Kahwash BM; Mathur SK; Simon D; Akuthota P; Holland N; Wetzler L; Ware JM; Guo C; Fay MP; Khoury P; Klion AD; Bochner BS
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
    Kuang FL; Klion AD
    J Allergy Clin Immunol Pract; 2017; 5(6):1502-1509. PubMed ID: 29122152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eosinophilic myositis with eosinophilic cellulitislike skin lesions. Association with increased serum levels of eosinophil cationic protein and interleukin-5.
    Trüeb RM; Lübbe J; Torricelli R; Panizzon RG; Wüthrich B; Burg G
    Arch Dermatol; 1997 Feb; 133(2):203-6. PubMed ID: 9041834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Therapies for Eosinophilic Disorders.
    Bochner BS
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):577-98. PubMed ID: 26209901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
    Ogbogu PU; Bochner BS; Butterfield JH; Gleich GJ; Huss-Marp J; Kahn JE; Leiferman KM; Nutman TB; Pfab F; Ring J; Rothenberg ME; Roufosse F; Sajous MH; Sheikh J; Simon D; Simon HU; Stein ML; Wardlaw A; Weller PF; Klion AD
    J Allergy Clin Immunol; 2009 Dec; 124(6):1319-25.e3. PubMed ID: 19910029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-IL-5 and hypereosinophilic syndromes.
    Sutton SA; Assa'ad AH; Rothenberg ME
    Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
    Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
    J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies.
    Legrand F; Cao Y; Wechsler JB; Zhu X; Zimmermann N; Rampertaap S; Monsale J; Romito K; Youngblood BA; Brock EC; Makiya MA; Tomasevic N; Bebbington C; Maric I; Metcalfe DD; Bochner BS; Klion AD
    J Allergy Clin Immunol; 2019 Jun; 143(6):2227-2237.e10. PubMed ID: 30543818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia.
    Kaya H; Gümüş S; Uçar E; Aydoğan M; Muşabak U; Tozkoparan E; Bilgiç H
    Chest; 2012 Aug; 142(2):513-516. PubMed ID: 22871762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders.
    Foroughi S; Foster B; Kim N; Bernardino LB; Scott LM; Hamilton RG; Metcalfe DD; Mannon PJ; Prussin C
    J Allergy Clin Immunol; 2007 Sep; 120(3):594-601. PubMed ID: 17765756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting interleukin (IL) 5 for asthma and hypereosinophilic diseases.
    Stein ML; Munitz A
    Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):201-9. PubMed ID: 20807192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eosinophilic disorders in children.
    Wagelie-Steffen A; Aceves SS
    Curr Allergy Asthma Rep; 2006 Nov; 6(6):475-82. PubMed ID: 17026874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].
    Guhl G; Díaz-Ley B; Fernández-Herrera J
    Actas Dermosifiliogr; 2008; 99(1):5-33. PubMed ID: 18206084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.